Repligen Corporation (RGEN)

Currency in USD
124.50
-3.39(-2.65%)
Real-time Data·
RGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
123.61129.00
52 wk Range
102.97175.77
Key Statistics
Prev. Close
127.89
Open
128.2
Day's Range
123.61-129
52 wk Range
102.97-175.77
Volume
502.15K
Average Vol. (3m)
716.12K
1-Year Change
-9.1248%
Book Value / Share
37.42
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RGEN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
186.28
Upside
+49.62%
Members' Sentiments
Bearish
Bullish
ProTips
12 analysts have revised their earnings downwards for the upcoming period

Repligen Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Repligen Corporation SWOT Analysis


Analyst Perspectives
Price targets range from $150 to $220, with an average of $172.50, reflecting varied views on Repligen's growth potential and market position
Market Expansion
Explore Repligen's growth from a $4B addressable market in 2020 to $12B in 2024, driven by new modalities and digitization initiatives
Financial Resilience
Q1 2025 revenue surpassed expectations at $169.2M, with revised full-year guidance of $695M-$720M, despite earnings per share missing forecasts
Bioprocessing Pionee
Repligen leads the bioprocessing industry with innovative products and strategic acquisitions, navigating market recovery and industry challenges
Read full SWOT analysis

Repligen Corporation Earnings Call Summary for Q4/2025

  • Repligen Q4 2025 EPS of $0.49 beat forecast by 11.36%; revenue reached $198M, up 18% YoY, exceeding expectations by 2.6%
  • Full-year 2025 revenue hit $738M (up 16% YoY); adjusted gross margin improved 170 bps to 52.4% driven by operational efficiency
  • Analytics and proteins franchises drove growth with 30%+ YoY increases; company projects 20%+ analytics growth and low double-digit gains in 2026
  • Stock dropped 8.43% in pre-market to $123.99 despite earnings beat, reflecting broader market concerns; down 17% YTD with RSI in oversold territory
  • Management emphasizes strategic initiatives and innovation focus; maintains strong balance sheet with 8.36 current ratio to support growth investments
Last Updated: 02/24/2026, 09:46 AM
Read Full Transcript

Compare RGEN to Peers and Sector

Metrics to compare
RGEN
Peers
Sector
Relationship
P/E Ratio
142.9x29.9x−0.5x
PEG Ratio
0.480.730.00
Price / Book
3.3x2.3x2.6x
Price / LTM Sales
9.5x1.8x3.2x
Upside (Analyst Target)
40.7%55.5%51.4%
Fair Value Upside
Unlock21.0%7.1%Unlock

Analyst Ratings

17 Buy
4 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 186.28
(+49.62% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Buy195.00+55.56%200.00MaintainFeb 25, 2026
KeyBanc
Buy220.00+75.51%-MaintainFeb 25, 2026
Barclays
Buy175.00+39.61%200.00MaintainFeb 25, 2026
UBS
Buy200.00+59.55%190.00MaintainJan 16, 2026
Wells Fargo
Buy190.00+51.58%175.00MaintainDec 15, 2025

Earnings

Latest Release
Feb 24, 2026
EPS / Forecast
0.49 / 0.44
Revenue / Forecast
197.91M / 192.89M
EPS Revisions
Last 90 days

RGEN Income Statement

People Also Watch

471.53
MEDP
-1.46%
346.74
CIEN
+8.85%
215.97
ZBRA
+1.02%
632.55
SNDK
+7.44%
91.73
RMBS
+3.62%

FAQ

What Is the Repligen (RGEN) Stock Price Today?

The Repligen stock price today is 124.50 USD.

What Stock Exchange Does Repligen Trade On?

Repligen is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Repligen?

The stock symbol for Repligen is "RGEN."

What Is the Repligen Market Cap?

As of today, Repligen market cap is 7.04B USD.

What Is Repligen's Earnings Per Share (TTM)?

The Repligen EPS (TTM) is 0.86.

When Is the Next Repligen Earnings Date?

Repligen will release its next earnings report on May 05, 2026.

From a Technical Analysis Perspective, Is RGEN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Repligen Stock Split?

Repligen has split 0 times.

How Many Employees Does Repligen Have?

Repligen has 2000 employees.

What is the current trading status of Repligen (RGEN)?

As of Mar 10, 2026, Repligen (RGEN) is trading at a price of 124.50 USD, with a previous close of 127.89 USD. The stock has fluctuated within a day range of 123.61 USD to 129.00 USD, while its 52-week range spans from 102.97 USD to 175.77 USD.

What Is Repligen (RGEN) Price Target According to Analysts?

The average 12-month price target for Repligen is 186.28 USD, with a high estimate of 220 USD and a low estimate of 152 USD. 17 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +49.62% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.